文献速递类风湿关节炎脊柱关节炎系统性红斑狼疮

JAK抑制剂治疗免疫介导炎症性疾病的考虑要点:系统文献研究

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research.
PubMed 文献 · RMD Open · 2020-01-01

该研究系统检索截至2019年3月的文献,评估JAK抑制剂在多种免疫介导炎症性疾病中的疗效与安全性。共纳入85篇文献,发现JAK抑制剂在类风湿关节炎、银屑病关节炎、强直性脊柱炎、系统性红斑狼疮等多种疾病中疗效优于安慰剂,安全性可接受,但感染风险增加。

要点

  • JAK抑制剂在多种免疫介导炎症性疾病中显示良好疗效
  • 安全性分析显示感染风险增加,尤其是带状疱疹
  • 未观察到恶性肿瘤或主要不良心血管事件发生率增加

核心结论

  • JAK抑制剂在多种免疫介导炎症性疾病中相比安慰剂显示良好疗效,在类风湿关节炎和银屑病中与TNF抑制剂相比也有良好疗效,安全性可接受。

研究设计与样本

  • 系统文献研究,检索MEDLINE、EMBASE和Cochrane Library截至2019年3月的文献,筛选3454篇摘要,最终纳入85篇文献(疗效和随机对照试验安全性分析72篇,仅安全性分析13篇)。

主要发现

  • 在类风湿关节炎中所有JAK抑制剂均显示疗效,银屑病关节炎(托法替布、非戈替尼)、强直性脊柱炎(托法替布、非戈替尼)、系统性红斑狼疮(巴瑞替尼)、慢性斑块状银屑病(托法替布、巴瑞替尼、培非替尼)、溃疡性结肠炎(托法替布、乌帕替尼)、克罗恩病(乌帕替尼、非戈替尼)和特应性皮炎(托法替布、巴瑞替尼、乌帕替尼)中也显示疗效。
  • 安全性分析显示感染风险增加,尤其是带状疱疹、严重感染,静脉血栓栓塞事件发生率数值上更高。
  • 未观察到恶性肿瘤发生率或主要不良心血管事件增加。

关键数值与推荐

  • 纳入6项JAK抑制剂与TNF抑制剂头对头比较试验。
  • 疗效评估涉及托法替布(27项)、巴瑞替尼(9项)、乌帕替尼(14项)、非戈替尼(7项)、decernotinib(3项)和培非替尼(7项)的随机对照试验。

临床怎么用

  • JAK抑制剂可用于多种免疫介导炎症性疾病的治疗,但需注意感染风险,尤其是带状疱疹和严重感染,并关注静脉血栓栓塞事件。

局限性

  • 文献检索截止2019年3月,未纳入之后发表的研究。
  • 安全性分析中静脉血栓栓塞事件仅为数值上更高,未报告统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Review of efficacy and safety of Janus kinase (JAK) inhibition in immune-mediated inflammatory diseases (IMIDs). METHODS: A systematic literature research (SLR) of all publications on JAK inhibitors (JAKi) treatment published until March 2019 using MEDLINE, EMBASE and the Cochrane Library. Efficacy and safety were assessed in randomised controlled trials (RCTs), integrating long-term extension periods additionally for safety evaluation. RESULTS: 3454 abstracts were screened with 85 included in the final analysis (efficacy and RCT safety: n=72; safety only: n=13). Efficacy of RCTs investigating tofacitinib (TOFA, n=27), baricitinib (BARI, n=9), upadacitinib (UPA, n=14), filgotinib (FILGO, n=7), decernotinib (DEC, n=3) and peficitinib (PEF, n=7) was evaluated. Six head-to-head trials comparing JAKi with tumour necrosis factor inhibitors (TNFi) were included. Efficacy of JAKi was shown in rheumatoid arthritis (RA) for all agents, psoriatic arthritis (TOFA, FILGO), ankylosing spondylitis (TOFA, FILGO), systemic lupus erythematosus (BARI), chronic plaque psoriasis (TOFA, BARI, PEF), ulcerative colitis (TOFA, UPA), Crohn's disease (UPA, FILGO) and atopic dermatitis (TOFA, BARI, UPA). Safety analysis of 72 RCTs, one cohort study and 12 articles on long-term extension studies showed increased risks for infections, especially herpes zoster, serious infections and numerically higher rates of venous thromboembolic events. No increased malignancy rates or major adverse cardiac events were observed. CONCLUSION: JAKi provide good efficacy compared to placebo (and to TNFi in RA and Pso) across various IMIDs with an acceptable safety profile. This SLR informed the task force on points to consider for the treatment of IMIDs with JAKi with the available evidence.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kerschbaumer A, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. RMD Open. 2020. PMID: 33188136. doi:10.1136/rmdopen-2020-001374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。